Tissue Phenomics Blog

5B_Her2-classified.jpg

Posts by Topic

see all

Topics:  Immunotherapy, personalized medicine, cancer diagnostics, precision medicine, cancer vaccines

Promising results with personalized cancer vaccines highlight the need for novel diagnostics to personalize cancer treatments

Aug 9, 2017 7:00:00 AM

Personalized medicine aims at bringing the right drug to the right patient at the right time. Getting many things right at the same time is challenging. There are many potential treatments for cancer patients and many of these can be combined with each other resulting in a lot of potential combination treatments. This growing number of treatment options makes it increasingly difficult to determine the right one for an individual patient. Biomarkers that help to predict response to a treatment are highly needed to guide treatment selection to maximize efficiency for both patients and payers.

Read More

Topics:  companion diagnostics, precision medicine, IVD, LDT, CDx strategy

Does it always take an IVD to be a CDx

Jul 10, 2017 7:30:00 AM

From the dawn of the Precision Medicine Age, pathologists have relied upon in vitro diagnostics (IVDs) to inform treating physicians of possible therapy options for cancer patients. From tests for HER2, EGFR, KRAS, and other biomarkers, IVDs have been more than sufficient to generate the necessary information to enable physicians to make educated treatment decisions. However, in the last few years, two pharmaceutical companies have successfully launched a drug with a sole-source lab commercializing a laboratory developed test (LDT). The first was AstraZeneca launching Lynparza™ requiring the use of Myriad Genetics’ BRACAnalysis CDx™ in December 2014, and the second was Clovis Oncology launching Rubraca™ requiring the use of Foundation Medicine’s FoundationFocus™ CDxBRCA in December 2016. It is still too early to know whether or not launching a CDx as a LDT is a new and sustainable trend, but it begs the question: Why would a pharma company select a lab as a CDx partner over an IVD manufacturer?

Read More

Topics:  image analysis, personalized medicine, biomarker, immuno-oncology, tissue diagnostics, companion diagnostics, tissue biomarkers, diagnostics, diagnostic test, precision medicine, biomarker signature

3 ways tissue image analysis will shape the future of cancer treatment with immunotherapies

Nov 7, 2016 1:00:00 AM

As healthcare continues its transition towards precision medicine, physicians are eager to maximize both the quantity and quality of data obtained from their patients’ tissue samples.  In the current “one drug, one test” paradigm, physicians struggle to balance the number of tests required to make a treatment decision with the limited amount of tissue that is available.  Further complicating treatment decisions is the use of imperfect biomarkers associated with targeted therapies, as the patients who are identified to be ideal candidates for a targeted therapy respond only some of the time while patients who are not expected to respond do.  This dilemma is of great concern for those who are responsible for paying for these expensive therapies - payers and patients – who would like to avoid unnecessary expenses for drugs that may not work and possibly cause debilitating side effects.  Of course, of even greater concern is helping the patient identify the best therapeutic option that allows them the best opportunity to treat their disease and maximize their quality and quantity of life.

Read More